|
TRI continues to grow a portfolio of early stage pharmaceutical and
biopharmaceutical investments. In addition to a strategic limited partnership with Pappas
Ventures, TRI has invested in the following companies:
Lectus Therapeutics Ltd.is a UK
biopharmaceutical company with an innovative, proprietary
functional proteomics screening platform (LEPTICS™), enabling
the discovery and development of novel, small molecule
modulators of ion channels.
Serenex Inc. is a chemoproteomics-oriented drug discovery
company focused on the discovery and development of novel therapeutics targeting cancer. The company’s innovative
proteome-mining technology provides unique, early insights into off- as well as on-target effects of drug candidates,
dramatically expediting the lead optimization process.
Adamas Pharmaceuticals, Inc. (formerly
NeuroMolecular Pharmaceuticals, Inc.) is a specialty pharmaceutical company focused on the development
and commercialization of improved combination therapeutics to treat important healthcare problems. The Company’s initial focus
is on novel therapeutics for neurological disorders.
Receptor Biologix Inc. is a biotechnology
company with facilities in Palo Alto, California. Founded on the discovery of Intron Fusion Proteins (IFPs) as
a new class of endogenous regulatory proteins, the company is now developing first-in-class, broad-spectrum
anticancer agents acting at known and novel anti-tumor targets.
Symphogen A/S is
an innovative Danish biotechnology company pioneering the
development of recombinant human polyclonal antibodies for the
treatment and prevention of human diseases including
inflammatory diseases and cancer. Symphogen’s therapeutic
antibodies – Symphobodies - mimic the diversity, affinity, and
specificity of the human immune response and are therefore
expected to offer advantages over current immunoglobulin and
monoclonal antibody therapies.
Xenon Pharmaceuticals Inc. is a leading
Canadian biopharmaceutical company using clinical genetic approaches to identify
novel targets for a wide range of significant human diseases. By isolating the key
genes underlying rare genetic disorders, the company has successfully identified
drug targets for several common complex diseases. TRI’s strategic investment will
support efforts to find novel targets that potentially will lead to the development
of innovative new treatments for atherosclerosis.
Patrys Ltd. is an innovative new biotechnology company pioneering the discovery and
development of human IgM antibodies for the treatment of a variety of cancers. Patrys
discovers potential human antibodies through its proprietary hybridoma technology.
CellCentric, Ltd. has established a network of exclusive relationships with more
than 20 of the world's leading laboratories working in epigenetics.
The company continues to build and manage a portfolio of novel
targets, screens and hit compounds important in the modulation of epigenetic phenomena, preparing
them for full scale pharmaceutical development.
Curidium Medica plc (CUR: LSE) specializes in the development of personalized
medicines by applying its proprietary HomoMatrixTM technology to stratify patient populations,
develop targeted medicines and identify companion diagnostics to treat patients with central
nervous system diseases more effectively. Curidium is working with Takeda on novel approaches
to the treatment of major depressive disorders
|
